With increased pressure on laboratory’s to decrease the costs of research and development, many labs in the Western world have been turning to automation to drive down costs. China, on the other hand, in now making an effort to automate various processes in the lab.

Numerous recent events meant that many Chinese pharma companies have come under fire for various reasons, such as violating standards in making vaccines for children, falling short of prescribed standards, or because of the recent FDA valsartan recall leading to a Chinese bulk manufacturer taking a large hit.

Despite these mistakes in these high-profile cases, experts say that China is still in a good position to take a leading place in global pharmaceutical production – especially if it progresses towards large-scale automation and process improvements. 

With increased pressure on laboratory’s to decrease the costs of research and development, many labs in the Western world have been turning to automation to drive down costs. China, on the other hand, in now making an effort to automate various processes in the lab.

Numerous recent events meant that many Chinese pharma companies have come under fire for various reasons, such as violating standards in making vaccines for children, falling short of prescribed standards, or because of the recent FDA valsartan recall leading to a Chinese bulk manufacturer taking a large hit.

Despite these mistakes in these high-profile cases, experts say that China is still in a good position to take a leading place in global pharmaceutical production – especially if it progresses towards large-scale automation and process improvements. 

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.